Funding opportunities We are constantly looking to fund research into developing new treatments and potential cures for AKU. The majority of our research is conducted in partnership with the University of Liverpool as well as a number of international partners. Below...
Other Research Gene therapy In partnership with the University of Liverpool, we have just begun a PhD programme looking at developing a gene therapy cure for AKU. We hope that the preliminary research conducted will create a foundation to explore the possibility of...
Hypertyrosinaemia We are currently conducting research into treating nitisinone-induced hypertyrosinaemia¹ in partnership with a number of collaborators including the University of Liverpool. Nitisinone is an extremely effective treatment which reduces homogentisic...
Diagnosis The diagnosis of AKU is made upon the identification of characteristic symptoms, patient history, and clinical evaluation. Identification of elevated levels of homogentisic acid (HGA) in the urine is indicative of AKU. AKU should be suspected of all...
Treatment AKU can be treated using the drug nitisinone. Our seven year DevelopAKUre study, which concluded in 2020, illustrated nitisinone effectively halts the build of homogentisic acid (HGA) by 99%. Nitisinone received a marketing authorisation from the European...
